Treatment News : HIV Med Selzentry (Maraviroc) Found to Fight Staph Infection

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » January 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


January 7, 2013

HIV Med Selzentry (Maraviroc) Found to Fight Staph Infection

The HIV antiretroviral Selzentry (maraviroc) combats the potentially lethal pathogen Staphylococcus aureus, the bacterium that causes staph infections, according to research from the New York University School of Medicine, redOrbit reports. Staph infections, which are the cause of hundreds of thousands of hospital admissions each year in the United States, are increasingly antibiotic-resistant. Publishing their findings in the journal Nature, the researchers discovered that a toxin called LukED that the bacterium excretes latches onto the same CCR5 coreceptor on the CD4 cell that HIV typically uses in order to gain entry. LukED then pierces holes through the CD4’s membrane, killing the cell.

Because Selzentry blocks the ability of the toxin to latch onto the CCR5’s coreceptor, it has the potential to thwart staph’s assault on the immune system. When the researchers treated CD4 cells with the antiretroviral in a laboratory setting, the drug totally blocked the toxic effects of LukED, which comes from a family known as leukotoxins. Researchers then examined the effects of CCR5 coreceptor inhibition in mice. Nearly all mice exposed to staph containing LukED died, while all those mice the scientists had genetically engineered to lack the CCR5 coreceptor survived the infection.

“The goal in blocking the toxin with maraviroc or similar agents is to give the upper hand to the immune system to better control the [staph] infection,” lead researcher Victor J. Torres, PhD, assistant professor of microbiology at NYU School of Medicine, said in a release.

The scientists hope the research will advance to human clinical trials.

To read the study abstract, click here

For the redOrbit story, click here.

Search: Selzentry, maraviroc, HIV, antiretroviral, staph infection, Staphylococcus aureus, bacterium, New York University School of Medicine, redOrbit, toxin, LukED, CCR5, coreceptor, CD4, Victor Torres.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Hide comments

Previous Comments:


[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.